GLTO

Galecto

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

Denmark

Next Earnings Date

17

Business Summary

Galecto is a clinical-stage biotechnology company focused on developing therapeutics for the treatment of fibrosis and cancer. The company's research centers on inhibiting galectin-3, a protein implicated in these disease processes.

 


Analyze GLTO on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$1,781

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

270.3

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$12.11

Next Year EPS Growth Estimate

-$1.07

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-197.90%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

0

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze GLTO on TradingView

Gainseekers Quantitative Analysis

Summary

GLTO is a biotechnology company with a market capitalization of $1,781 million that is currently unprofitable, as shown by its EPS of -$12.11 and a Return on Equity of -197.90%. The company has no debt relative to its equity and trades at a very high Price / Book multiple of 270.3. Institutional ownership stands at a low 1.90%, while 11.70% of the company’s float is held by short sellers.

AI Exposure / Tech Reliance

The provided financial data does not contain specific metrics regarding the company's AI exposure or reliance on technology.

The Bull Case

The bull case is supported by a strong consensus rating of 1.4 and a mean target price of $46.75, alongside an analyst expectation for EPS to improve to -$1.07 next year. Furthermore, the company maintains a clean balance sheet with a debt-to-equity ratio of 0.

The Bear Case

The bear case centers on the company's significant unprofitability, evidenced by a -197.90% Return on Equity and an EPS of -$12.11. Concerns are compounded by a high Price / Book ratio of 270.3, a notable short interest of 11.70% of the float, and very low institutional ownership of 1.90%.

Market Sentiment & Smart Money

Short Interest %

11.70%

Analyst Consensus

1.4

Average Analyst Price Target

$46.75

Institutional Ownership %

1.90%

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.